AZ31 is a potent, highly selective and orally active ATM inhibitor with enzyme IC50 of <1.2 nM, cell IC50 of 46 nM.
AZ31 displays excellent selectivity against a panel of kinases including ATR, DNAPK, mTOR, PI3Kα, PI3Kβ, PI3Kγ, GSK3β and KDR.
AZ31 reduces upregulation of p21 and blocks G1 arrest in wild-type but not Cdkn1a(p21CIP/WAF1)-/- mice.
AZ31 showes significant tumor growth reduction in the SW620 xenograft model combined with irinotecan.
